Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Emel Tumbay is active.

Publication


Featured researches published by Emel Tumbay.


Mycoses | 2006

Onychomycosis in primary school children: association with socioeconomic conditions.

Turan Gündüz; Dilek Yeşim Metin; Tuncer Saçar; Suleyha Hilmioglu; Hakan Baydur; Ramazan Inci; Emel Tumbay

Onychomycosis in childhood is reported to be unusual. The aim of this study was to determine the prevalence of onychomycosis in primary school children and to make comparison between different socioeconomic status in the rural and urban areas of the city. Hand and foot nails of 23235 children aged 7–14 were examined. Onychomycosis was suspected and nail scrapings for mycological examination were taken in 116 of them. Hyphae or spores were seen in 41 (0.18%) by direct microscopic examination, and mycological cultures were positive in 24 (0.1%) of them. Toenails were affected in all of the fungal culture positive cases. Trichosporon spp, Trichophyton rubrum, Candida albicans and Candida glabrata grew in 11, 6, 5 and 2 of the cultures repectively. Onychomycosis prevalence was significantly higher in the children living in the rural areas (p = 0.016) [Odds ratio = 3.43 (%95 CI 1.11


Mycopathologia | 2011

Evaluation of Antifungal Susceptibility Testing with Microdilution and Etest Methods of Candida Blood Isolates

Dilek Yeşim Metin; Süleyha Hilmioğlu-Polat; Pinar Samlioglu; Biray Doganay-Oflazoglu; Ramazan Inci; Emel Tumbay

Candida species that show an increasing number of clinical and/or microbiological resistance to several antifungals and are the most common agents of invasive fungal infections. The aim of this study was to investigate the in vitro susceptibility of Candida blood isolates to antifungal agents (amphotericin B, fluconazole, itraconazole, and voriconazole) by comparative use of the CLSI reference microdilution method and Etest. Four hundred Candida blood isolates (215 Candidaalbicans, 185 non-albicansCandida strains) were included in the study. The broth microdilution test was performed according to the CLSI M27 A2 document. Etest was carried out according to the manufacturer’s instructions. The MIC results obtained with reference microdilution were compared with those obtained with the Etest by using percent and categorical agreements. According to MIK90 values, voriconazole was the most active and itraconazole was the least active drug in vitro against all Candida species. Other than voriconazole, statistically significant differences were found when the susceptibility of Candida albicans and non-albicans Candida spp. to amphotericin B, fluconazole, and itraconazole were compared. These antifungal agents were found to be more active to C. albicans. Among the non-albicansCandida species, the lowest MIC values were obtained for Candida parapsilosis isolates. When the standard method was compared with Etest, the total agreement was higher for C. albicans than for non-albicans species, especially for fluconazole and voriconazole. In view of the findings, it was concluded that itraconazole showed the lowest activity against all Candida species. Etest could be an alternative method in assessing the in vitro antifungal susceptibility of Candida spp., but it is more convenient to use the microdilution method for studying in vitro susceptibility of non-albicans species, in particular for those possessing high MIC values against azoles.


Mycoses | 2018

Estimated burden of serious human fungal diseases in Turkey

Süleyha Hilmioğlu-Polat; Seyedmojtaba Seyedmousavi; Macit Ilkit; Mohammad Taghi Hedayati; Ramazan Inci; Emel Tumbay; David W. Denning

The current number of fungal infections occurring each year in Turkey is unknown. We estimated the burden of serious human fungal diseases based on the population at risk, existing epidemiological data from 1920 to 2017 and modelling previously described by the LIFE program (http://www.LIFE-worldwide.org). Among the population of Turkey (80.8 million in 2017), approximately 1 785 811 (2.21%) people are estimated to suffer from a serious fungal infection each year. The model used predicts high prevalences of allergic fungal rhinosinusitis episodes (312 994 cases) (392/100 000), of severe asthma with fungal sensitisation (42 989 cases) (53.20 cases/100 000 adults per year), of allergic bronchopulmonary aspergillosis (32 594 cases) (40.33/100 000), of fungal keratitis (26 671 cases) (33/100 000) and of chronic pulmonary aspergillosis (5890 cases) (7.29/100 000). The estimated annual incidence for invasive aspergillosis is lower (3911 cases) (4.84/100 000 annually). Among about 22.5 million women aged 15‐50 years, recurrent vulvovaginal candidiasis is estimated to occur in 1 350 371 (3342/100 000) females. The burden of three superficial fungal infections was also estimated: tinea pedis (1.79 million), tinea capitis (43 900) and onychomycosis (1.73 million). Given that the modelling estimates reported in the current study might be substantially under‐ or overestimated, formal epidemiological and comprehensive surveillance studies are required to validate or modify these estimates.


Annals of Saudi Medicine | 2015

Skin infection on both legs caused by Acremonium strictum (case report).

Suleyha Hilmioglu; Dilek Yeşim Metin; Meltem Tasbakan; Hüsnü Pullukçu; Tamer Akalin; Emel Tumbay

Acremonium species are saprophytic molds widely distributed in nature, existing in soil and decaying vegetation. Penetrating wounds, intravascular catheters and immunosuppression are risk factors for invasive infections of Acremonium. The fungus can also cause cutaneous infections and mycetoma in the immunocompetent; such infections occur in extremities open to trauma. In this paper, a female patient with skin infection due to Acremonium strictum in both legs is described.


Mycopathologia | 2005

Non-dermatophytic molds as agents of onychomycosis in Izmir, Turkey - a prospective study.

Süleyha Hilmioğlu-Polat; Dilek Yeşim Metin; Ramazan Inci; T. Dereli; I. Kılınç; Emel Tumbay


Mycoses | 2009

ber die DNase-Aktivitt von Hefestmmen

Emel Tumbay; H. P. R. Seeliger


Mycoses | 2009

Über die DNase‐Aktivität von Hefestämmen

Emel Tumbay; H. P. R. Seeliger


Fems Immunology and Medical Microbiology | 2003

Erratum to âEditorialâ

Emel Tumbay


Fems Immunology and Medical Microbiology | 2003

Erratum to “Editorial”: [FEMS Immunol. Med. Mircobiol. 35 (2003) 171]

Emel Tumbay


Fems Immunology and Medical Microbiology | 2003

Erratum to “Editorial”

Emel Tumbay

Collaboration


Dive into the Emel Tumbay's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge